KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy

Radiotherapy and Oncology

Volumn 94, Issue 1, 2010, Pages 76-81

  Gaedcke, Jochen ^a   Grade, Marian ^a   Jung, Klaus ^a   Schirmer, Markus ^a   Jo, Peter ^a   Obermeyer, Christoph ^a   Wolff, Hendrik A ^b   Herrmann, Markus K ^b   Beissbarth, Tim ^a   Becker, Heinz ^a   Ried, Thomas ^c   Ghadimi, Michael ^a  

^a Department of General and Visceral Surgery ^*

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

BRAF; KRAS; Preoperative chemoradiotherapy; Rectal cancer; Response

Indexed keywords

AMINO ACID; B RAF KINASE; DNA; FLUOROURACIL; K RAS PROTEIN; OXALIPLATIN;

ADULT; AGED; ARTICLE; BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CODON; CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DNA ISOLATION; EXON; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PARAMETER; PRIORITY JOURNAL; RECTUM CANCER; TUMOR REGRESSION;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PREOPERATIVE CARE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 74549208605     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2009.10.001     Document Type: Article

References (36)

1. Hoshino R., Chatani Y., Yamori T., et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18 (1999) 813-822
2. Wang L., Cunningham J.M., Winters J.L., et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 63 (2003) 5209-5212
3. Karnoub A.E., and Weinberg R.A. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 9 (2008) 517-531
4. Karapetis C.S., Khambata-Ford S., Jonker D.J., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359 (2008) 1757-1765
5. Van Cutsem E., Kohne C.H., Hitre E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360 (2009) 1408-1417
6. Andreyev H.J., Norman A.R., Cunningham D., et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 85 (2001) 692-696
7. Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
8. Wan P.T., Garnett M.J., Roe S.M., et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116 (2004) 855-867
9. Yuen S.T., Davies H., Chan T.L., et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 62 (2002) 6451-6455
10. Storm S.M., and Rapp U.R. Oncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors. Toxicol Lett 67 (1993) 201-210
11. Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B., and Velculescu V.E. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418 (2002) 934
12. Di Nicolantonio F., Martini M., Molinari F., et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26 (2008) 5705-5712
13. Sauer R., Becker H., Hohenberger W., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351 (2004) 1731-1740
14. Rodel C., and Sauer R. Integration of novel agents into combined-modality treatment for rectal cancer patients. Strahlenther Onkol 183 (2007) 227-235
15. Heald R.J., and Ryall R.D. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1 (1986) 1479-1482
16. Grade M., Ghadimi B.M., Varma S., et al. Aneuploidy-dependent massive deregulation of the cellular transcriptome and apparent divergence of the Wnt/beta-catenin signaling pathway in human rectal carcinomas. Cancer Res 66 (2006) 267-282
17. Ghadimi B.M., Grade M., Difilippantonio M.J., et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 23 (2005) 1826-1838
18. Gavioli M., Bagni A., Piccagli I., Fundaro S., and Natalini G. Usefulness of endorectal ultrasound after preoperative radiotherapy in rectal cancer: comparison between sonographic and histopathologic changes. Dis Colon Rectum 43 (2000) 1075-1083
19. Kim J.C., Cho Y.K., Roh S.A., et al. Individual tumorigenesis pathways of sporadic colorectal adenocarcinomas are associated with the biological behavior of tumors. Cancer Sci 99 (2008) 1348-1354
20. Fransen K., Klintenas M., Osterstrom A., Dimberg J., Monstein H.J., and Soderkvist P. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 25 (2004) 527-533
21. Debucquoy A., Haustermans K., Daemen A., et al. Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. J Clin Oncol 27 (2009) 2751-2757
22. Horisberger K., Treschl A., Mai S., et al. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a phase II MARGIT trial. Int J Radiat Oncol Biol Phys 74 (2009) 1487-1493
23. Rodel C., Grabenbauer G.G., Papadopoulos T., Hohenberger W., Schmoll H.J., and Sauer R. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 21 (2003) 3098-3104
24. Feig L.A., and Cooper G.M. Relationship among guanine nucleotide exchange, GTP hydrolysis, and transforming potential of mutated ras proteins. Mol Cell Biol 8 (1988) 2472-2478
25. Edkins S., O'Meara S., Parker A., et al. Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther 5 (2006) 928-932
26. Tol J., Koopman M., Cats A., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360 (2009) 563-572
27. Lurje G., Nagashima F., Zhang W., et al. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin Cancer Res 14 (2008) 7884-7895
28. Grana T.M., Rusyn E.V., Zhou H., Sartor C.I., and Cox A.D. Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways. Cancer Res 62 (2002) 4142-4150
29. Gupta A.K., Bakanauskas V.J., Cerniglia G.J., et al. The Ras radiation resistance pathway. Cancer Res 61 (2001) 4278-4282
30. Luna-Perez P., Segura J., Alvarado I., Labastida S., Santiago-Payan H., and Quintero A. Specific c-K-ras gene mutations as a tumor-response marker in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Ann Surg Oncol 7 (2000) 727-731
31. Rodel C., Martus P., Papadoupolos T., et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23 (2005) 8688-8696
32. Zauber N.P., Marotta S.P., Berman E., et al. Molecular genetic changes associated with colorectal carcinogenesis are not prognostic for tumor regression following preoperative chemoradiation of rectal carcinoma. Int J Radiat Oncol Biol Phys 74 (2009) 472-476
33. Bazan V., Migliavacca M., Zanna I., et al. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 13 (2002) 1438-1446
34. Guerrero S., Figueras A., Casanova I., et al. Codon 12 and codon 13 mutations at the K-ras gene induce different soft tissue sarcoma types in nude mice. FASEB J 16 (2002) 1642-1644
35. Guerrero S., Casanova I., Farre L., Mazo A., Capella G., and Mangues R. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res 60 (2000) 6750-6756
36. Monticone M., Biollo E., Maffei M., et al. Gene expression deregulation by KRAS G12D and G12V in a BRAF V600E context. Mol Cancer 7 (2008) 92